《异基因造血干细胞移植治疗多发性骨髓瘤.ppt》由会员分享，可在线阅读，更多相关《异基因造血干细胞移植治疗多发性骨髓瘤.ppt（93页珍藏版）》请在三一办公上搜索。
1、Allogeneic haematopoietic cell transplantation for multiplemyeloma,The allogeneic transplant has the advantage over the autologous transplantThe graft does not contain tumor cells and the potential for a graft versus myeloma(GvM)effect,Bone marrow transplantation in three patients with multiple myel
2、oma Gahrton G,Ringdn O,Lnnqvist B,Lindquist R,Ljungman P.,Acta Med Scand 1986;219(5):523-7.,瑞典卡罗林斯卡医学院 1983,Myeloablative conditioning,Three patients with multiple myeloma received bone marrow grafts from HLA-identical sibling donorsOne of the patients,with IgA kappa myeloma,refractory to alkeran-pr
3、ednisone therapy,is well and still without sign of disease 26 months post transplantation A second patient with Bence-Jones kappa myeloma is well,and skeletal pain and Bence-Jones proteinuria has disappeared 2 months after transplantation.A third patient with IgG-lambda myeloma died of effusive peri
4、carditis shortly after transplantation.,Acta Med Scand 1986;219(5):523-7,Conclusion,Bone marrow transplantation may be indicated in a selective group of patients with multiple myeloma,Acta Med Scand 1986;219(5):523-7,Out of 690 allogenetic matched sibling donor transplants for MM 344 were performed
5、during the period 1983-93(all with BM)group 1356 during 1994-98(223 with BM group 2 and 133 with PB group 3),the median age at transplantation of patients in group 1 was 43 years(range 21-62)In group 2,44 years(range 18_57)and in group 3,46 years(range 25_60),TBI+CY tended to be more commonly used i
6、n group 1(37%)and 2(39%)than in group 3(27%)Melphalan containing regimes tended to be morely used in group 3 Melphalan or Busulphan+CY rarely,Conditiong regime,Engraftment,GVHD,Treatment related mortality,Treatment related mortality,Relapse rate,Relapse rate,Survival,Survival,Progression free surviv
7、al,PFS was significantly better for group 2than for group 1(P0.0001)With no significantly difference between group 2 and 3,Cause of death,75%in group 1,36%in group 2,33%in group 3 GVHDFungal ARDSOrgan failure,Cause of death,the study shows that the improvement is entirely a result of a lower TRM dur
8、ing the latest 5-years period aGVHD has no changed during this peroid There was significant difference in deaths caused by IP and bacterial and fungalinfection,Conditioning regime,TBI+Melphalan has not previrous been Shown to be superior to TBI+CY in this study,conclusion,Survival 3060%Treatment rel
9、ated mortality30%,Myeloablative allogeneic versus autologous transplantation,during the years 1983 to 1994189 myeloma patients who underwent allo-BMT with an HLA-identical sibling donor were compared retrospectively with an equal number of patients who received a single autologous bone marrow or blo
10、od stem cell graftAnd the ASCT patients were transplanted from 1986 to 1994,conclusionThe overall survival was significantly better for ASCT than for allo-BMT,with a median survival of 34 months and 18 months,respectively(P=.001),The main reason for the poorer survival in allo-BMT patients was highe
11、r TRM(41%v 13%for ASCT,P=.0001),which was not compensated for by a lower rate of relapse and progression,conclusionHowever,in patients alive at 1 year posttransplant,there was a trend for better long-term survival(P=.O9)and significantly better progression-free survival(P=.02)for allo-BMT as compare
12、d with ASCTWe conclude that the median survival is superior for ASCTHowever,allo-BMT has a lower relapse rate,which results in a similar long-term outcome for both approaches,but a longer follow-up is needed to assess the final outcome,Reduced-intensity conditioning allogeneic transplantation,The Al
13、lo-RIC was introduced in an attempt to decrease the transplant-related toxicity while retaining the beneficial GvM effect1998 begin clinical study,19982003We report the outcome of 229 patientswho received an allograft for myelomawith reduced-intensity conditioning(RIC)regimens from 33 centers within
14、 the EBMT.,With a median follow-up of 28 months,115 patients are alive(range,1-53 months)The estimated overall survival at 3 years is 40.6%(CI,33%-49%)The treatment-related mortalities at day 100,1 year,and 2 years were 10%,22%,and 26%,respectively.The cumulative probability of the progression-free
15、survival was 21.3%(CI,15%-29%)at 3years,ConclusionWhile RIC is feasible,heavily pretreated patients and patients with progressive disease do not benefit,RIC vs MAC,Data were available on a total of 516 patients from 103 centers:320 patients with RIC and 196 with MAC.between January 1,1998,to Decembe
16、r 31,2002The median follow-up was 28 months,conclusion RIC was associated with a reduction in TRM but this was offset by an increase in relapse risk the conditioning intensity did not impact on overall survival or retain significance for PFSThese data suggest that there is a continuing need to inves
17、tigate dose intensity in the conditioning for myeloma allografts.,Tandem autologous/Allo-RIC transplantation,Autologous hematopoietic cell transplantation(HCT)followed by nonmyeloablative allogeneic HCT(auto/alloHCT)provides cytoreduction and graft-versus-myeloma effects.,弗雷德哈钦森癌症研究中心,Patient inclus
18、ion criteria for this analysis were stage II or III MM at diagnosis available human leukocyte antigen(HLA)identical sibling donor programmed sequential treatment with conventional autologous HCT followed by nonmyeloablative auto/alloHCT no prior autologous HCT.,105 patients with MM fulfilling those
19、criteria were sequentially enrolled at 10 centers on 4 FHCRC-coordinated multiinstitutional protocols from August 1998 to August 2005 Patients proceeded to allogeneic HCT 40 to 180 days after autografting,Autologous HCT.(G-CSF)mobilized peripheral blood mononuclear cells(G-PBMC)were harvested by leu
20、kapheresis after treatment with cyclophosphamide 3 to 4 g/m2(day 1)and G-CSF 10 g/kg subcutaneously(from day 3 through collection),Autologous HCT38 patients received additional paclitaxel(250 mg/m2 per day,day 2),and 25 received additional etoposide(200 mg/m2 per day;days 1,2,3)and dexamethasone(10
21、mg/day orally;days 1,2,3,4)Two patients received G-CSF alone.,Autologous HCTNo treatment for MM was given between autologous and allogeneic HCT,Allogeneic HCT After recovery from autologous HCT102 patientsproceeded to allotransplantation.Donors were HLA-identical siblings,Nonmyeloablative conditioni
22、ng consisted in all patients of 2 Gy total body irradiation(TBI)at 7 cGy/min by linear accelerator or cobalt on day 027 patients received additional fludarabine(30 mg/m2)on days 4,3,and 2,N,%,EngraftmentAll 102 allografted patients had sustained engraftment.On day 28,medians of 90%,95%,and 95%of per
23、ipheral blood T cells,granulocytes,and nucleated marrow cells,respectively,were of donor origin.This increased to medians of 96%to 100%on day 84,GVHD43 patients(42%)developed grades 2 to 4 acute GVHD at a median of 42(range,8-107)days74 patients(74%)developed chronic extensive GVHD at a median of 16
24、7(range,90-830)days after transplantation.,NRMNRM was 1%at day 100 and 11%,14%,and 18%at 1,2,and 5 years after allografting,respectivelyGVHD and infections were responsible for 18 of 19 non relapse related deaths.,Overall and progression-free survivalsAfter a median follow-up of 6.3 years after allo
25、grafting(range 2-9)60 of 102(59%)patients survived and 33 of 102(32%)are in remissionFive-year estimated OS and PFS were 64%and 36%,respectively,conclusionauto/allo-RIC HCT is a treatment option for patients with advanced stage MMThe addition of novel agents(eg,thalidomide,bortezomib,and lenalidomid
26、e)as induction or postgrafting therapy,acting with GVM effects against disease-specific antigens,might further improve the outcome.,improve the outcomeThalidomide/lenalidomidedexamethasoneBortezomib,研究所佩奥利-Calmettes，马赛，法国,This was a retrospective study from 3 centers 37 patients treated between Nove
27、mber 2003 and March 2007,conclusionbortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.,Double autologous Versus tandem auto/Allo-RIC transplantation,圣乔凡尼巴蒂斯塔大学医院，都灵，意大利,Methods All patients were initially treated with VAD followed by melphalan and autologous stem-cell
28、rescue,Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling.Patientswithout an HLA-identical sibling received two consecutive myeloablative doses of melphalan,each of which was followed by autologous stem-cell rescue.The primary
29、 end points were overall survival and event-free survival.,ConclusionsAmong patients with newly diagnosed myeloma,survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts.,UNSOLVED QUESTIONS IN ALLOGENEIC TRANSPLANTATIONWhich is the best allogeneic transplantation approach?Who are the patients most likely to benefit from Allo-RIC?How to improve the results of Allo-RIC?,
